On January 1, 2025, Cigna Healthcare^® began an oncology drug dose rounding program to reduce drug waste for a variety of injectable oncology drugs while maintaining a therapeutic response.

To optimize drug dosage, drugs included in the program are rounded down to the nearest vial size when the difference between the prescribed drug and vial size is within 5 to 10 percent. This follows the recommendation of the Hematology/Oncology Pharmacy Association and is endorsed by the American Society of Clinical Oncology, and the National Comprehensive Cancer Network^®.

Considerations

• EviCore by Evernorth^® manages all prior authorizations for oncology drugs. You will notice changes to the EviCore prior authorization website when prescribing one of the impacted drugs. For more information about this change, please refer to the quick reference guide.
• Drugs in multi-dose vials, oral chemotherapeutics, erythropoiesis-stimulating agents, radioactive drugs, and drugs with flat doses are excluded from this program.

Updated drug list for the oncology drug dose rounding program

The drugs included in the program are listed below. Effective July 7, 2025, the nine drugs shown at the top of the list will be added to the original list of oncology drugs listed in the table below.